Literature DB >> 12074817

Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy.

Jürgen E Gschwend1, Philipp Dahm, William R Fair.   

Abstract

OBJECTIVE: To directly compare disease specific and overall survival as endpoints in the outcome analysis of a large number of cystectomy patients and to define predictors for survival.
MATERIALS AND METHODS: We retrospectively analyzed the records of 686 patients who underwent bilateral pelvic lymph node dissection (PLND) and radical cystectomy from 1980 to 1990 at Memorial Sloan-Kettering Cancer Center.
RESULTS: Disease specific survival characterized a clearly more favorable patient outcome than overall survival in the entire patient population as well as patients with organ confined (OC) and non-organ-confined disease (NOC): 10-year disease specific and overall survival rates for patients with OC disease (<or=P3a), negative nodes or NOC (>or=P3b) were 72.9% versus 49.1%, 61.7% versus 40.8% and 33.3% versus 22.8%, respectively. In node positive (N+) patients 10-year disease specific and overall survival rates were 27.7% and 20.9%, respectively. In a multivariate analysis organ confinement and nodal status were the strongest independent predictors of disease specific survival in all patient categories. However, stratification according to organ confinement and nodal status revealed additional prognostic parameters.
CONCLUSION: Organ-confined bladder cancer translates into high disease specific survival rates following radical cystectomy. Outcome is best characterized by disease-specific survival versus overall survival, which underestimates the impact of treatment in patients with favorable tumor and nodal stage. Subgroup analysis of patients with organ confinement and nodal status identified additional prognostic variables within the more favorable patient categories not apparent in the entire population. The poor prognosis of patients with NOC and/or N+ tumors emphasized the importance of future randomized trials in which such stratification variables may be of value.

Entities:  

Mesh:

Year:  2002        PMID: 12074817     DOI: 10.1016/s0302-2838(02)00060-x

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  25 in total

1.  [Detection of lymphovascular invasion in urothelial carcinoma of the bladder through D2-40 immunostaining].

Authors:  T Martini; P Ströbel; A Steidler; N Petrakopoulou; P Erben; C Bolenz
Journal:  Urologe A       Date:  2015-01       Impact factor: 0.639

Review 2.  [Noninvasive and invasive bladder cancer: diagnostics and treatment].

Authors:  P J Goebell; F Vom Dorp; C Rödel; D Frohneberg; J W Thüroff; D Jocham; C Stief; S Roth; R Knüchel; K W Schmidt; I Kausch; D Zaak; C Wiesner; K Miller; R Sauer; H Rübben
Journal:  Urologe A       Date:  2006-07       Impact factor: 0.639

3.  Bladder cancer: narrowing the gap between evidence and practice.

Authors:  Maha H A Hussain; David P Wood; Dean F Bajorin; Bernard H Bochner; Robert Dreicer; Donald L Lamm; Michael A O'Donnell; Arlene O Siefker-Radtke; Dan Theodorescu; Colin P Dinney
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

4.  In-vitro cytocidal effect of water on bladder cancer cells: The potential role for intraperitoneal lavage during radical cystectomy.

Authors:  Rikiya Taoka; Stephen B Williams; Philip L Ho; Ashish M Kamat
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

5.  Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis.

Authors:  Jack Crozier; Nathan Papa; Marlon Perera; Brian Ngo; Damien Bolton; Shomik Sengupta; Nathan Lawrentschuk
Journal:  World J Urol       Date:  2018-08-17       Impact factor: 4.226

6.  Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics.

Authors:  Evelyne Lerut; Hendrik Van Poppel; Steven Joniau; Olivier Gruselle; Thierry Coche; Patrick Therasse
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

7.  Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study.

Authors:  T Grimm; A Buchner; B Schneevoigt; A Kretschmer; M Apfelbeck; M Grabbert; J F Jokisch; C G Stief; A Karl
Journal:  World J Urol       Date:  2015-09-16       Impact factor: 4.226

8.  The prognostic role of pre-cystectomy hemoglobin levels in patients with invasive bladder cancer.

Authors:  Tina Schubert; Tilman Todenhöfer; Johannes Mischinger; Christian Schwentner; Markus Renninger; Arnulf Stenzl; Georgios Gakis
Journal:  World J Urol       Date:  2015-09-29       Impact factor: 4.226

Review 9.  [Multimodal therapy for bladder sparing with high grade bladder tumors].

Authors:  P J Goebell; W Legal; C Weiss; R Fietkau; B Wullich; S Krause
Journal:  Urologe A       Date:  2008-07       Impact factor: 0.639

10.  Role of pelvic lymphadenectomy in the treatment of bladder cancer: a mini review.

Authors:  Ja Hyeon Ku
Journal:  Korean J Urol       Date:  2010-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.